SS
NKGN

SBI Securities’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

SBI Securities’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-902
Closed -$591 – 4238
2024
Q4 		$591 Buy
+902
New +$368 ﹤0.01% 2833

Other funds holding NKGN

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $323M AUM 14.1% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

SBI Securities's NKGN Position: Q1 2025 in Review

SBI Securities sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2025, closing a stake of 902 shares — an estimated $591 sold.

SBI Securities first reported a position in NKGN in Q4 2024 and held it in 1 quarter. The position peaked at $591 in Q4 2024. 3 funds tracked by Wall St. Rank hold NKGN as of Q1 2025.

  • SBI Securities reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • SBI Securities sold 902 NKGen Biotech, Inc. Common Stock shares in Q1 2025, an estimated $591.
  • SBI Securities first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
  • SBI Securities's NKGen Biotech, Inc. Common Stock position peaked at $591 in Q4 2024.
  • 3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2025.

Based on SBI Securities's 13F filing for Q1 2025, filed 2 May 2025.